Hydrocortisone in Severe Community-Acquired Pneumonia (CAP)
Clinical Lecture Notes
Indications
- Target population: Adult patients hospitalized with severe bacterial CAP, typically managed in the ICU setting.
- Key clinical triggers:
- Acute hypoxemic respiratory failure requiring advanced respiratory support: high-flow nasal cannula (HFNC), non-invasive ventilation (NIV), or invasive mechanical ventilation (IMV).
- Septic shock requiring vasopressor support.
- Clinical guidelines (SCCM 2024):
- Strong recommendation supporting corticosteroid use in severe bacterial CAP.
- Routine use is not recommended for non-severe CAP or stable floor/ward patients.
- Important exclusions and caution:
- Do not routinely extrapolate to influenza pneumonia or primary viral pneumonia.
- Use extreme caution in patients with active fungal infections or severe baseline immunosuppression.
Dosing Regimens
- Standard dosage: Hydrocortisone 200 mg/day IV.
- Administration modes: Continuous IV infusion (200 mg/day) or intermittent IV push (50 mg q6h).
- Usual duration: 5 to 7 days based on clinical response; total dose should generally not exceed 400 mg/day.
- CAPE-COD trial protocol:
- Induction: Hydrocortisone 200 mg/day IV for the first 4 days.
- Responders (clinical improvement by Day 4): Taper down for an 8-day total course.
- Non-responders (inadequate improvement by Day 4): Continue 200 mg/day through Day 7, followed by a taper for a 14-day total course.
- Key trial outcome:
- 28-day all-cause mortality: 6.2% with hydrocortisone vs 11.9% with placebo.
Clinical Pearls and Monitoring
- Timing: Start early following ICU admission, concurrently with appropriate empiric antibiotic therapy, source control, and hemodynamic/respiratory stabilization.
- Overlap with septic shock: If septic shock is the dominant presentation, hydrocortisone 50 mg IV q6h fits standard stress-dose septic shock management; distinguish CAP response from shock reversal.
- Safety and monitoring:
- Hyperglycemia: The most frequent adverse effect; requires routine blood glucose monitoring and glycemic control protocols.
- Secondary infections: CAPE-COD demonstrated no statistically significant rise in hospital-acquired infections, but vigilance remains necessary.
- Gastrointestinal bleeding: No significant increase in GI bleeding was observed in CAPE-COD; use standard ICU stress ulcer prophylaxis as indicated.
- Neuromuscular weakness: Monitor for ICU-acquired weakness with extended courses.
Summary Takeaway
For severe bacterial CAP requiring ICU care, starting hydrocortisone at 200 mg/day IV for 5 to 7 days (with subsequent clinical response-guided tapering) provides an evidence-based, practical initial regimen.
Lecture Notes - Critical Care and Emergency Medicine Reference
